Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Gut
    March 2026
  1. HENS B, D'Haens G, Ungaro RC, Colombel JF, et al
    Screening for preclinical Crohn's disease based on capsule endoscopy is not yet ready.
    Gut. 2026 Mar 2:gutjnl-2026-338303. doi: 10.1136/gutjnl-2026-338303.
    >> Share

    February 2026

  2. Correction: Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2026 Feb 18:gutjnl-2024-332043corr1. doi: 10.1136/gutjnl-2024-332043.
    >> Share

  3. POWELL N
    Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?
    Gut. 2026 Feb 13:gutjnl-2025-336049. doi: 10.1136/gutjnl-2025-336049.
    >> Share

  4. DAI C, Huang YH, Jiang M
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives.
    Gut. 2026 Feb 3:gutjnl-2026-338123. doi: 10.1136/gutjnl-2026-338123.
    >> Share

  5. TURNER D, Kenigsberg S, Focht G, Croitoru K, et al
    Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.
    Gut. 2026 Feb 3:gutjnl-2026-338188. doi: 10.1136/gutjnl-2026-338188.
    >> Share

    January 2026
  6. IACUCCI M, Zammarchi I, Pugliano CL, Santacroce G, et al
    Shaping the future of postoperative recurrence in Crohn's disease: personalised approaches with AI-enabled imaging and multi-omics.
    Gut. 2026 Jan 27:gutjnl-2025-337171. doi: 10.1136/gutjnl-2025-337171.
    >> Share

  7. PARIGI TL, Cominelli F
    Role of TL1A in perianal fistulising Crohn's disease: a new therapeutic target?
    Gut. 2026 Jan 23:gutjnl-2025-337684. doi: 10.1136/gutjnl-2025-337684.
    >> Share

  8. CONSTANTINE-COOKE N, Gros B, Plevris N, Williams LJ, et al
    Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.
    Gut. 2026 Jan 19:gutjnl-2025-337846. doi: 10.1136/gutjnl-2025-337846.
    >> Share

  9. ZHANG J, Mak JWY, Ng SC
    Gut microbiome in IBD: past, present and the future.
    Gut. 2026;75:398-410.
    >> Share

  10. MAYORGA L, Noguera Segura A, Campderros L, Pons-Tarin M, et al
    Distinct microbial mediators link diet to inflammation in Crohn's disease and ulcerative colitis.
    Gut. 2026 Jan 6:gutjnl-2025-337480. doi: 10.1136/gutjnl-2025-337480.
    >> Share

    December 2025
  11. NOH Y, Choi A, Lee H, Yon DK, et al
    Proton pump inhibitors use and risk of inflammatory bowel disease in children.
    Gut. 2025 Dec 31:gutjnl-2025-337345. doi: 10.1136/gutjnl-2025-337345.
    >> Share

  12. GUDINO V, Cho JW, Caballol B, Sanzo-Machuca A, et al
    TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.
    Gut. 2025 Dec 25:gutjnl-2025-336246. doi: 10.1136/gutjnl-2025-336246.
    >> Share

  13. ZHOU L, Nie J, Feng Z, Li R, et al
    Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn's disease.
    Gut. 2025 Dec 13:gutjnl-2025-336415. doi: 10.1136/gutjnl-2025-336415.
    >> Share

  14. TURNER D, Kenigsberg S, Focht G, Turpin W, et al
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
    Gut. 2025 Dec 11:gutjnl-2025-336368. doi: 10.1136/gutjnl-2025-336368.
    >> Share

  15. SCHREIBER S, Aden K, Tran F, Rosenstiel P, et al
    Rise of precision medicine: can it deliver on its promise in IBD?
    Gut. 2025;75:176-188.
    >> Share

  16. MIYAUCHI E, Taida T, Uchiyama K, Nakanishi Y, et al
    Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota.
    Gut. 2025;75:46-56.
    >> Share

  17. DE LUCA R, Arre V, Nardone S, Incerpi S, et al
    Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.
    Gut. 2025;75:161-175.
    >> Share

    October 2025
  18. BRAGA-NETO MB, Qazi T, Fulmer C, Holubar SD, et al
    Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.
    Gut. 2025;74:1905-1915.
    >> Share

    September 2025

  19. Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025 Sep 26:gutjnl-2024-334395corr1. doi: 10.1136/gutjnl-2024-334395.
    >> Share

  20. ASHTON JJ, Green Z, Beattie RM
    British Society of Gastroenterology adult guidelines on inflammatory bowel disease: what can we learn for children and young people?
    Gut. 2025 Sep 12:gutjnl-2025-336739. doi: 10.1136/gutjnl-2025-336739.
    >> Share

  21. HAZIME H, Ducasa GM, Santander AM, Brito N, et al
    DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis.
    Gut. 2025;74:1589-1601.
    >> Share

  22. GONZALEZ-ACERA M, Patankar JV, Erkert L, Cineus R, et al
    Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD.
    Gut. 2025;74:1602-1615.
    >> Share

    August 2025
  23. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global consensus statement on the management of pregnancy in inflammatory bowel disease.
    Gut. 2025 Aug 28:gutjnl-2025-336402. doi: 10.1136/gutjnl-2025-336402.
    >> Share

    July 2025
  24. MO M, Sun J, Mikulic I, Ludvigsson JF, et al
    Inflammatory bowel disease linked to accelerated cognitive decline in individuals with dementia: a nationwide cohort study.
    Gut. 2025 Jul 11:gutjnl-2025-335370. doi: 10.1136/gutjnl-2025-335370.
    >> Share


  25. Correction: Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025;74:e16.
    >> Share

  26. KOU F, Li XY, Feng Z, Hua J, et al
    GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
    Gut. 2025;74:1279-1292.
    >> Share

  27. BOURGONJE AR, Andreu-Sanchez S, Gacesa R, Innocenti G, et al
    Crohn's disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset.
    Gut. 2025 Jul 2:gutjnl-2024-334362. doi: 10.1136/gutjnl-2024-334362.
    >> Share

    June 2025
  28. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Small intestinal contrast ultrasound versus imaging and enteroscopy in Crohn's disease.
    Gut. 2025 Jun 27:gutjnl-2025-335697. doi: 10.1136/gutjnl-2025-335697.
    >> Share

  29. MORAN GW, Gordon M, Sinopolou V, Radford SJ, et al
    British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025;74.
    >> Share

  30. SUN Y, Huang X, Zhang Y, Bao W, et al
    Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn's disease by inducing gut dysbiosis.
    Gut. 2025 Jun 8:gutjnl-2024-334604. doi: 10.1136/gutjnl-2024-334604.
    >> Share

  31. BARNICH N, Arthur JC, Buisson A, Campbell BJ, et al
    Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
    Gut. 2025 Jun 5:gutjnl-2025-335331. doi: 10.1136/gutjnl-2025-335331.
    >> Share

    May 2025
  32. ALKHATEB O, Ftouni R, Abbas O, Mourad FH, et al
    Skin lesions and chest pain in a patient with Crohn's disease.
    Gut. 2025 May 24:gutjnl-2025-335547. doi: 10.1136/gutjnl-2025-335547.
    >> Share

  33. BLACKWELL J, Plevris N, Bancil A, Kobayashi T, et al
    Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025 May 13:gutjnl-2025-334946. doi: 10.1136/gutjnl-2025-334946.
    >> Share

  34. PAL P, Mateen MA, Sekaran A, Pooja K, et al
    Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?
    Gut. 2025 May 13:gutjnl-2025-335681. doi: 10.1136/gutjnl-2025-335681.
    >> Share

    April 2025
  35. EAST JE, Gordon M, Nigam GB, Sinopoulou V, et al
    British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease.
    Gut. 2025 Apr 30:gutjnl-2025-335023. doi: 10.1136/gutjnl-2025-335023.
    >> Share

  36. TSCHURTSCHENTHALER M
    Dietary modulation of the gut phageome: a cross-kingdom dialogue in Crohn's disease.
    Gut. 2025 Apr 29:gutjnl-2025-335261. doi: 10.1136/gutjnl-2025-335261.
    >> Share

  37. WAN Z, Hao X, Huang F, Dai H, et al
    Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies.
    Gut. 2025 Apr 19:gutjnl-2024-334693. doi: 10.1136/gutjnl-2024-334693.
    >> Share

    March 2025
  38. SU R, Wen W, Jin Y, Cao Z, et al
    Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome.
    Gut. 2025 Mar 23:gutjnl-2024-334516. doi: 10.1136/gutjnl-2024-334516.
    >> Share

  39. BAMIAS G, Menghini P, Pizarro TT, Cominelli F, et al
    Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.
    Gut. 2025;74:652-668.
    >> Share

    February 2025
  40. GUISADO D, Talware S, Wang X, Davis A, et al
    Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
    Gut. 2025 Feb 17:gutjnl-2024-333558. doi: 10.1136/gutjnl-2024-333558.
    >> Share

  41. GUDINO V, Bartolome-Casado R, Salas A
    Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications.
    Gut. 2025 Feb 4:gutjnl-2024-334165. doi: 10.1136/gutjnl-2024-334165.
    >> Share

    January 2025
  42. AL BAKIR I, Curtius K, Cresswell GD, Grant HE, et al
    Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis.
    Gut. 2025 Jan 29:gutjnl-2024-333353. doi: 10.1136/gutjnl-2024-333353.
    >> Share

  43. BONFILS L, Poulsen G, Agrawal M, Julsgaard M, et al
    Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
    Gut. 2025;74:206-213.
    >> Share

  44. TE GROEN M, Wijnands AM, den Broeder N, de Jong DJ, et al
    Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS).
    Gut. 2025 Jan 16:gutjnl-2024-333446. doi: 10.1136/gutjnl-2024-333446.
    >> Share

    December 2024
  45. ZHANG J
    Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota.
    Gut. 2024 Dec 23:gutjnl-2024-333425. doi: 10.1136/gutjnl-2024-333425.
    >> Share

  46. GISBERT JP, Donday MG, Riestra S, Lucendo AJ, et al
    Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2024 Dec 20:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385.
    >> Share

  47. ADLER J, Gadepalli S, Rahman M, Kim S, et al
    Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study.
    Gut. 2024 Dec 12:gutjnl-2024-333280. doi: 10.1136/gutjnl-2024-333280.
    >> Share

  48. NEURATH MF, Sands BE, Rieder F
    Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
    Gut. 2024;74:9-14.
    >> Share

    November 2024
  49. AMIOT A, Seksik P, Meyer A, Stefanescu C, et al
    Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
    Gut. 2024 Nov 25:gutjnl-2024-333281. doi: 10.1136/gutjnl-2024-333281.
    >> Share

  50. WELLENS J, Sabino J, Vanuytsel T, Tack J, et al
    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
    Gut. 2024 Nov 12:gutjnl-2024-333565. doi: 10.1136/gutjnl-2024-333565.
    >> Share

    October 2024
  51. LV X, Zeng Y, Ma W, Zheng Y, et al
    Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn's disease.
    Gut. 2024 Oct 14:gutjnl-2024-333590. doi: 10.1136/gutjnl-2024-333590.
    >> Share

  52. VICH VILA A, Zhang J, Liu M, Faber KN, et al
    Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
    Gut. 2024;73:1909-1920.
    >> Share

    September 2024
  53. ERKERT L, Gamez-Belmonte R, Kabisch M, Schodel L, et al
    Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
    Gut. 2024;73:1618-1631.
    >> Share

  54. CARPAY N, de Boer NKH, Neefjes-Borst A, Bots S, et al
    Severe multiple therapy refractory colitis in a 46-year-old man.
    Gut. 2024;73:1617-1736.
    >> Share

    August 2024
  55. ESTEVINHO MM, Midya V, Cohen-Mekelburg S, Allin KH, et al
    Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
    Gut. 2024 Aug 30:gutjnl-2024-332523. doi: 10.1136/gutjnl-2024-332523.
    >> Share

  56. PIERRE N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, et al
    External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
    Gut. 2024 Aug 12:gutjnl-2024-332648. doi: 10.1136/gutjnl-2024-332648.
    >> Share

  57. JACOBS JP, Spencer EA, Helmus DS, Yang JC, et al
    Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
    Gut. 2024 Aug 9:gutjnl-2024-332475. doi: 10.1136/gutjnl-2024-332475.
    >> Share

  58. ATREYA R
    Glowing insights: tracking vedolizumab in the mucosa of patients with IBD via molecular endoscopy.
    Gut. 2024;73:1406-1408.
    >> Share

  59. VERSTOCKT B, Vancamelbeke M, Vermeire S
    Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease.
    Gut. 2024;73:1586-1588.
    >> Share

  60. MAJUMDER S, Santacroce G, Maeda Y, Zammarchi I, et al
    Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis.
    Gut. 2024 Aug 6:gutjnl-2024-332894. doi: 10.1136/gutjnl-2024-332894.
    >> Share

    July 2024
  61. DAI C, Huang YH
    Rare cause of liver lesion in a patient with ulcerative colitis.
    Gut. 2024 Jul 20:gutjnl-2024-333095. doi: 10.1136/gutjnl-2024-333095.
    >> Share

  62. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    >> Share

  63. ADOLPH TE, Meyer M, Jukic A, Tilg H, et al
    Heavy arch: from inflammatory bowel diseases to metabolic disorders.
    Gut. 2024;73:1376-1387.
    >> Share

    June 2024
  64. DENNISON TW, Edgar RD, Payne F, Nayak KM, et al
    Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2024 Jun 10:gutjnl-2024-332043. doi: 10.1136/gutjnl-2024-332043.
    >> Share

  65. IACUCCI M, Santacroce G, Majumder S, Morael J, et al
    Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia.
    Gut. 2024 Jun 8:gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579.
    >> Share

  66. LIN S, Wang J, Mukherjee PK, Mao R, et al
    Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis.
    Gut. 2024;73:1110-1123.
    >> Share

  67. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    >> Share

  68. HONAP S, Jairath V, Sands BE, Dulai PS, et al
    Acute severe ulcerative colitis trials: the past, the present and the future.
    Gut. 2024 Jun 4:gutjnl-2024-332489. doi: 10.1136/gutjnl-2024-332489.
    >> Share

    May 2024
  69. MONAGHAN TM, Ugun-Klusek A, Finelli M, Gurnani P, et al
    Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention.
    Gut. 2024;73:1034-1036.
    >> Share

    April 2024
  70. GABRIELS RY, van der Waaij AM, Linssen MD, Dobosz M, et al
    Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
    Gut. 2024 Apr 5:gutjnl-2023-331696. doi: 10.1136/gutjnl-2023-331696.
    >> Share

  71. RIEDER F, Mukherjee PK, Massey WJ, Wang Y, et al
    Fibrosis in IBD: from pathogenesis to therapeutic targets.
    Gut. 2024;73:854-866.
    >> Share

  72. KARMI N, Sun S, Festen EAM, Vich Vila A, et al
    Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
    Gut. 2024 Apr 3:gutjnl-2024-332205. doi: 10.1136/gutjnl-2024-332205.
    >> Share

    March 2024
  73. ANANTHAKRISHNAN AN
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.
    >> Share

  74. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    >> Share

    February 2024
  75. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    >> Share

  76. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    >> Share

  77. ADOLPH TE
    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.
    >> Share

  78. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    >> Share

    January 2024
  79. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    >> Share

  80. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.
    >> Share

  81. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    >> Share

    December 2023
  82. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    >> Share

  83. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.
    >> Share

    November 2023
  84. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    >> Share

  85. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    >> Share

  86. NEURATH MF, Vieth M
    Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing.
    Gut. 2023;72:2164-2183.
    >> Share

    October 2023
  87. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    >> Share

    September 2023
  88. MA Y, Zhang X, Xuan B, Li D, et al
    Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
    Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
    >> Share

  89. JIANG L, Li JC, Shen L, Tang BS, et al
    Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
    Gut. 2023;72:1797-1799.
    >> Share

  90. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
    British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
    Gut. 2023;72:1631-1634.
    >> Share

    August 2023
  91. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
    Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
    Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.
    >> Share

  92. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
    Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
    Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.
    >> Share

  93. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
    Microbiome variance of the small bowel in Crohn's disease.
    Gut. 2023;72:1626-1628.
    >> Share

    July 2023
  94. BECKER C, Adolph TE
    Disentangling tryptophan metabolism in inflammatory bowel diseases.
    Gut. 2023;72:1235-1236.
    >> Share

  95. LEE JC
    Going deeper: molecular inflammatory scores in IBD.
    Gut. 2023;72:1233-1234.
    >> Share

  96. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
    Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
    Gut. 2023;72:1296-1307.
    >> Share

  97. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
    Biopsy and blood-based molecular biomarker of inflammation in IBD.
    Gut. 2023;72:1271-1287.
    >> Share

    June 2023
  98. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
    Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
    Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
    >> Share

  99. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
    The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
    Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
    >> Share

  100. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
    TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
    Gut. 2023;72:1101-1114.
    >> Share

  101. MILLET V, Gensollen T, Maltese M, Serrero M, et al
    Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
    Gut. 2023;72:1115-1128.
    >> Share

  102. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
    CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
    Gut. 2023;72:1081-1092.
    >> Share

    May 2023
  103. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
    Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
    Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
    >> Share

  104. LU H, Zhang C, Wu W, Chen H, et al
    MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
    Gut. 2023;72:882-895.
    >> Share

  105. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
    Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
    Gut. 2023;72:870-881.
    >> Share

    April 2023
  106. GHATE A, Uhlig HH
    Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
    Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.
    >> Share

  107. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
    Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
    Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
    >> Share

  108. ZHAO J, Chen J, Sun Y, Yuan S, et al
    Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
    Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.
    >> Share

  109. YE BD
    Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
    Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
    >> Share

  110. HSU NY, Nayar S, Gettler K, Talware S, et al
    NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
    Gut. 2023;72:654-662.
    >> Share

  111. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
    Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
    Gut. 2023;72:804-805.
    >> Share

    March 2023
  112. FAYE AS, Jess T
    Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
    Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.
    >> Share

  113. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
    Faecal metabolome and its determinants in inflammatory bowel disease.
    Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
    >> Share

  114. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
    Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
    Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
    >> Share

  115. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
    Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
    Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016